Condition
HER2-positive unresectable locally recurrent or metastatic breast cancer (MBC).
Total Trials
1
Recruiting
0
Active
1
Completed
0
Key Insights
Highlights
Treatment Research
3 treatments under study, led by Trastuzumab Deruxtecan
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 1 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
1Total
Phase 2 (1)
Trial Status
Active Not Recruiting1
Clinical Trials (1)
Showing 1 of 1 trials
Showing all 1 trials
Research Network
Common Treatments
- Trastuzumab Deruxtecan1
- Phesgo 1200 Mg 600 Mg 30000 Unt Per 15 Ml Injection1
- Phesgo 600 Mg 600 Mg 20000 Unt In 10 Ml Injection1
Active Sponsors
- MedSIR1
- Roche1
- Medica Scientia Innovation Research S.L.1
Top Investigators
Arnau de Vilanova Hospital, Valencia (Spain)
International Breast Cancer Center (Spain)
Institute of Breast Cancer, Quirón Group, Barcelona (Spain)
Related Conditions
- Her2positive Breast Cancer1